Drug Profile
Research programme: protein-based therapies - Valitor
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Valitor
- Class Eye disorder therapies; Proteins; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Eye disorders; Musculoskeletal disorders; Skin disorders
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Eye-disorders in USA
- 28 Aug 2020 No recent reports of development identified for preclinical development in Musculoskeletal-disorders in USA
- 28 Aug 2020 No recent reports of development identified for preclinical development in Skin-disorders in USA